A number of new promising agents for the prevention of acute and chronic transplant rejection have been or are being developed. In this Review, Antoine Durrbach and colleagues discuss agents that interfere with antibody-mediated rejection and those that deplete allogenic T cells or inhibit T-cell activation. The capacity of these agents to prevent acute rejection is also described.
- Antoine Durrbach
- Helene Francois
- Bernard Charpentier
